TP53 and cancer: Molecularly, the BRAFmut/MSS cancers did not differ from BRAFwt/MSS cancers with extent of p53 mutation (21/57, 37% versus 42/90, 47%), but were significantly more likely to demonstrate CIMP (27/47, 57% versus 3/79, 4%) (p<0.0001) (Table 1).